Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis-Reference-Cited by-同舟云学术

Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis

Published:2022-09 Issue: Volume:177 Page:103760
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Yang Fei,Zhang Wengang,Shang Xiaoling,Liu Ni,Ma Xinchun,Qin Jing,Zhang Yuqing,Liu Yanguo,Wang Xiuwen

Funder

National Natural Science Foundation of China

Natural Science Foundation of Shandong Province

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference86 articles.

1. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity;Ballard;Clin. Cancer Res,2016

2. General methods for monitoring convergence of iterative simulations;Brooks;J. Comput. Graph. Stat.,1998

3. Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer;Castellanos;J. Thorac. Oncol.,2017

4. Non-small-cell lung cancers: a heterogeneous set of diseases;Chen;Nat. Rev. Cancer,2014

5. Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations;Cheng;J. Clin. Oncol.,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR- mutated NSCLC: a network meta-analysis;2024-09-11

2. Non-small cell lung cancer: an update on emerging EGFR-targeted therapies;Expert Opinion on Emerging Drugs;2024-04-02

3. Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study;Translational Lung Cancer Research;2023-11

4. Comparative efficacy and safety of almonertinib and osimertinib for advanced non-cellular lung cancer: a real-world non-inferiority study;2023-09-19

5. Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis;Frontiers in Pharmacology;2023-07-06